PL374096A1 - Pyrrolopyrimidines as protein kinase inhibitors - Google Patents

Pyrrolopyrimidines as protein kinase inhibitors

Info

Publication number: PL374096A1
Authority: PL; Poland
Prior art keywords: pyrrolopyrimidines; protein kinase; kinase inhibitors; inhibitors; protein
Prior art date: 2001-06-23

Application number

PL02374096A

Other languages

Polish (pl)

Inventor

Paul Joseph Cox

Tahir Nadeem Majid

Shelley Amendola

Stephanie Daniele Deprets

Chris Edlin

Brian Leslie Pedgrift

Frank Halley

Michael Edwards

Bernard Baudoin

Lain Mcfarlane Mclay

David John Aldous

Original Assignee

Aventis Pharmaceuticals Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-06-23

Filing date

2002-06-21

Publication date

2005-09-19

2002-06-21 Application filed by Aventis Pharmaceuticals Inc. filed Critical Aventis Pharmaceuticals Inc.

2005-09-19 Publication of PL374096A1 publication Critical patent/PL374096A1/en

Links

229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
239000003909 protein kinase inhibitor Substances 0.000 title 1
150000004944 pyrrolopyrimidines Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Immunology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Otolaryngology (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

PL02374096A 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors PL374096A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0115393.1A GB0115393D0 (en)	2001-06-23	2001-06-23	Chemical compounds
US30167801P	2001-06-28	2001-06-28

Publications (1)

Publication Number	Publication Date
PL374096A1 true PL374096A1 (en)	2005-09-19

Family

ID=9917225

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL02374096A PL374096A1 (en)	2001-06-23	2002-06-21	Pyrrolopyrimidines as protein kinase inhibitors

Country Status (22)

Country	Link
EP (1)	EP1404676A1 (en)
JP (1)	JP4344607B2 (en)
CN (1)	CN1294135C (en)
AU (1)	AU2002314325B8 (en)
BR (1)	BR0210652A (en)
CA (1)	CA2451932C (en)
CZ (1)	CZ20033443A3 (en)
EA (1)	EA007415B1 (en)
EC (1)	ECSP034922A (en)
EE (1)	EE05432B1 (en)
GB (1)	GB0115393D0 (en)
HU (1)	HUP0400300A3 (en)
ME (1)	MEP19308A (en)
NZ (1)	NZ529766A (en)
OA (1)	OA12632A (en)
PL (1)	PL374096A1 (en)
RS (1)	RS51698B (en)
SK (1)	SK15882003A3 (en)
TN (1)	TNSN03144A1 (en)
TR (1)	TR200302242T2 (en)
UA (1)	UA76760C2 (en)
WO (1)	WO2003000695A1 (en)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
GB0202679D0 (en) *	2002-02-05	2002-03-20	Glaxo Group Ltd	Novel compounds
BR0313059B8 (en)	2002-07-29	2021-07-27	Rigel Pharmaceuticals	compound, and, pharmaceutical composition
CN102358738A (en)	2003-07-30	2012-02-22	里格尔药品股份有限公司	2,4-pyrimidinediamine compounds and uses of treating or preventing autoimmune diseases thereof
JP2007511596A (en) *	2003-11-17	2007-05-10	ファイザー・プロダクツ・インク	Pyrrolopyrimidine compounds useful in the treatment of cancer
CA2545192A1 (en) *	2003-11-25	2005-06-09	Pfizer Products Inc.	Method of treatment of atherosclerosis
US20050250829A1 (en) *	2004-04-23	2005-11-10	Takeda San Diego, Inc.	Kinase inhibitors
US7550598B2 (en)	2004-08-18	2009-06-23	Takeda Pharmaceutical Company Limited	Kinase inhibitors
FR2876103B1 (en)	2004-10-01	2008-02-22	Aventis Pharma Sa	NOVEL BIS-AZAINDOL DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS INHIBITORS OF KINASES
DE602005023333D1 (en)	2004-10-15	2010-10-14	Takeda Pharmaceutical	KINASE INHIBITORS
FR2878849B1 (en)	2004-12-06	2008-09-12	Aventis Pharma Sa	SUBSTITUTED INDOLES, COMPOSITIONS CONTAINING SAME, METHOD OF MANUFACTURE AND USE
CA2607901C (en)	2005-06-13	2016-08-16	Rigel Pharmaceuticals, Inc.	Methods and compositions for treating degenerative bone disorders using a syk inhibitory 2,4-pyrimidinediamine
US8119655B2 (en)	2005-10-07	2012-02-21	Takeda Pharmaceutical Company Limited	Kinase inhibitors
CN103214484B (en)	2005-12-13	2016-07-06	因塞特控股公司	Pyrrolo-[2,3-b] pyridine replaced as the heteroaryl of Janus inhibitors of kinases and pyrrolo-[2,3-b] pyrimidine
SG158147A1 (en)	2006-10-09	2010-01-29	Takeda Pharmaceutical	Kinase inhibitors
HUE029236T2 (en)	2007-06-13	2017-02-28	Incyte Holdings Corp	Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
WO2009098715A2 (en)	2008-01-11	2009-08-13	Natco Pharma Limited	Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents
RU2015105591A (en)	2008-06-10	2015-08-10	Эббви Инк.	NEW TRICYCLIC COMPOUNDS
MY156727A (en)	2009-05-22	2016-03-15	Incyte Corp	N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP2432472B1 (en)	2009-05-22	2019-10-02	Incyte Holdings Corporation	3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
WO2011018894A1 (en) *	2009-08-10	2011-02-17	Raqualia Pharma Inc.	Pyrrolopyrimidine derivatives as potassium channel modulators
TW201113285A (en)	2009-09-01	2011-04-16	Incyte Corp	Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2011029043A1 (en)	2009-09-04	2011-03-10	Biogen Idec Ma Inc.	Heteroaryl btk inhibitors
JP5607174B2 (en)	2009-12-01	2014-10-15	アッヴィ・インコーポレイテッド	New tricyclic compounds
EP3354652B1 (en)	2010-03-10	2020-05-06	Incyte Holdings Corporation	Piperidin-4-yl azetidine derivatives as jak1 inhibitors
AR084691A1 (en)	2010-05-21	2013-06-05	Incyte Corp	TOPICAL USE FORMULATION FOR A JAK INHIBITOR AND METHOD TO TREAT SKIN DISORDER
WO2012068440A1 (en)	2010-11-19	2012-05-24	Incyte Corporation	Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
CA2818542A1 (en)	2010-11-19	2012-05-24	Incyte Corporation	Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
CN102093364B (en)	2011-01-07	2015-01-28	北京赛林泰医药技术有限公司	2,4-diamido-6,7-dihydro-5H-pyrrolo [2,3] pyrimidine derivative as focal adhesion kinase/pyruvate kinase 2 (FAK/Pyk2) inhibitor
CN103476776B (en) *	2011-01-07	2016-09-28	北京赛林泰医药技术有限公司	2,4-diaminourea-6,7-dihydro-5H-pyrrolo-[2,3] pyrimidine derivatives as FAK/Pyk2 inhibitor
MY165963A (en)	2011-06-20	2018-05-18	Incyte Holdings Corp	Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
TW201313721A (en)	2011-08-18	2013-04-01	Incyte Corp	Cyclohexyl azetidine derivatives as JAK inhibitors
UA111854C2 (en)	2011-09-07	2016-06-24	Інсайт Холдінгс Корпорейшн	METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
WO2013157022A1 (en)	2012-04-20	2013-10-24	Advinus Therapeutics Limited	Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
TW201406761A (en)	2012-05-18	2014-02-16	Incyte Corp	Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
DK2877467T3 (en)	2012-07-26	2017-02-13	Glaxo Group Ltd	2- (AZAINDOL-2-YL) BENZIMIDAZOLES AS PAD4 INHIBITORS
CN104981247A (en) *	2012-09-06	2015-10-14	普莱希科公司	Compounds and methods for kinase modulation, and indications therefor
TWI761825B (en)	2012-11-15	2022-04-21	美商英塞特控股公司	Sustained-release dosage forms of ruxolitinib
MX384910B (en)	2013-03-06	2025-03-14	Incyte Holdings Corp	PROCESSES AND INTERMEDIATE FOR MAKING A JAK INHIBITOR.
TW201444820A (en)	2013-03-13	2014-12-01	Abbvie Inc	Pyridine CDK9 kinase inhibitors
MX2015012386A (en)	2013-03-13	2016-02-03	Abbvie Inc	Cdk9 kinase inhibitors.
MX2015012153A (en) *	2013-03-14	2015-12-01	Abbvie Inc	Pyrrolopyrimindine cdk9 kinase inhibitors.
UY35419A (en)	2013-03-14	2014-10-31	Abbvie Inc	PIRROLO KINASA CDK9 INHIBITORS (2,3- B) PIRIDINE
JP2016514113A (en)	2013-03-14	2016-05-19	アッヴィ・インコーポレイテッド	Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitor
SG11201600815WA (en)	2013-08-07	2016-03-30	Incyte Corp	Sustained release dosage forms for a jak1 inhibitor
CN104804001B9 (en) *	2014-01-24	2022-02-08	江苏柯菲平医药股份有限公司	4-substituted pyrrolo [2,3-d ] pyrimidine compounds and uses thereof
WO2015184305A1 (en)	2014-05-30	2015-12-03	Incyte Corporation	TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
US11780848B2 (en)	2015-10-16	2023-10-10	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US11524964B2 (en)	2015-10-16	2022-12-13	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en)	2015-10-16	2020-02-04	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en)	2015-10-16	2022-11-29	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en)	2015-10-16	2022-06-21	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
SG10201913999PA (en)	2015-10-16	2020-03-30	Abbvie Inc	PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US12365689B2 (en)	2015-10-16	2025-07-22	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
TWI851536B (en)	2017-03-09	2024-08-11	美商艾伯維有限公司	Methods of treating crohn’s disease and ulcerative colitis
US11564922B2 (en)	2017-03-09	2023-01-31	Abbvie Inc.	Methods of treating crohn's disease and ulcerative colitis
US10596161B2 (en)	2017-12-08	2020-03-24	Incyte Corporation	Low dose combination therapy for treatment of myeloproliferative neoplasms
JP7393348B2 (en)	2018-01-30	2023-12-06	インサイト・コーポレイション	Process and intermediates for producing (1-(3-fluoro-2(trifluoromethyl)isonicotinyl)piperidin-4-one)
CN113768934A (en)	2018-03-30	2021-12-10	因赛特公司	Treatment of hidradenitis suppurativa with JAK inhibitors
PT3860998T (en)	2018-10-05	2024-04-02	Annapurna Bio Inc	Compounds and compositions for treating conditions associated with apj receptor activity
US11833155B2 (en)	2020-06-03	2023-12-05	Incyte Corporation	Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU1441497A (en) *	1996-01-23	1997-08-20	Novartis Ag	Pyrrolopyrimidines and processes for their preparation
CA2272705C (en) *	1996-11-27	2003-03-18	Pfizer Inc.	Fused bicyclic pyrimidine derivatives
PA8474101A1 (en) *	1998-06-19	2000-09-29	Pfizer Prod Inc	PYROLEUM [2,3-D] PIRIMIDINE COMPOUNDS
PL198640B1 (en) *	1998-06-19	2008-07-31	Pfizer Prod Inc	PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
HK1039325B (en) *	1998-09-18	2006-02-24	Abbott Gmbh & Co. Kg	4-aminopyrrolopyrimidines as kinase inhibitors
EA006227B1 (en) *	1999-12-10	2005-10-27	Пфайзер Продактс Инк.	PIRROLO(2,3-d)PYRIMIDINE COMPOUNDS

2001
- 2001-06-23 GB GBGB0115393.1A patent/GB0115393D0/en not_active Ceased
2002
- 2002-06-21 CN CNB028119320A patent/CN1294135C/en not_active Expired - Fee Related
- 2002-06-21 RS YU99203A patent/RS51698B/en unknown
- 2002-06-21 AU AU2002314325A patent/AU2002314325B8/en not_active Ceased
- 2002-06-21 CZ CZ20033443A patent/CZ20033443A3/en unknown
- 2002-06-21 UA UA2004010502A patent/UA76760C2/en unknown
- 2002-06-21 WO PCT/GB2002/002835 patent/WO2003000695A1/en not_active Ceased
- 2002-06-21 OA OA1200300335A patent/OA12632A/en unknown
- 2002-06-21 ME MEP-193/08A patent/MEP19308A/en unknown
- 2002-06-21 BR BR0210652-3A patent/BR0210652A/en not_active Application Discontinuation
- 2002-06-21 EA EA200400073A patent/EA007415B1/en not_active IP Right Cessation
- 2002-06-21 JP JP2003507098A patent/JP4344607B2/en not_active Expired - Fee Related
- 2002-06-21 NZ NZ529766A patent/NZ529766A/en not_active IP Right Cessation
- 2002-06-21 EP EP02740895A patent/EP1404676A1/en not_active Withdrawn
- 2002-06-21 EE EEP200400003A patent/EE05432B1/en not_active IP Right Cessation
- 2002-06-21 PL PL02374096A patent/PL374096A1/en not_active Application Discontinuation
- 2002-06-21 CA CA002451932A patent/CA2451932C/en not_active Expired - Fee Related
- 2002-06-21 HU HU0400300A patent/HUP0400300A3/en unknown
- 2002-06-21 TR TR2003/02242T patent/TR200302242T2/en unknown
- 2002-06-21 TN TNPCT/GB2002/002835A patent/TNSN03144A1/en unknown
- 2002-06-21 SK SK1588-2003A patent/SK15882003A3/en not_active Application Discontinuation
2003
- 2003-12-23 EC EC2003004922A patent/ECSP034922A/en unknown

Also Published As

Publication number	Publication date
CA2451932C (en)	2009-12-29
JP4344607B2 (en)	2009-10-14
CN1518552A (en)	2004-08-04
EP1404676A1 (en)	2004-04-07
HUP0400300A3 (en)	2010-12-28
GB0115393D0 (en)	2001-08-15
SK15882003A3 (en)	2004-07-07
AU2002314325B8 (en)	2009-01-29
ECSP034922A (en)	2004-04-28
CZ20033443A3 (en)	2004-03-17
RS99203A (en)	2006-12-15
EA200400073A1 (en)	2004-08-26
NZ529766A (en)	2008-11-28
CA2451932A1 (en)	2003-01-03
EE05432B1 (en)	2011-06-15
WO2003000695A1 (en)	2003-01-03
BR0210652A (en)	2004-08-10
RS51698B (en)	2011-10-31
TNSN03144A1 (en)	2005-12-23
JP2005508300A (en)	2005-03-31
EA007415B1 (en)	2006-10-27
TR200302242T2 (en)	2004-12-21
OA12632A (en)	2006-06-14
UA76760C2 (en)	2006-09-15
WO2003000695A8 (en)	2004-03-11
MEP19308A (en)	2010-06-10
AU2002314325B2 (en)	2009-01-08
CN1294135C (en)	2007-01-10
EE200400003A (en)	2004-02-16
HUP0400300A2 (en)	2007-08-28

Legal Events

Date	Code	Title	Description
2014-05-30	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
HUP0400300A3 (en)	2010-12-28	Pyrrolopyrimidines as protein kinase inhibitors
IL159506A0 (en)	2004-06-01	Pyrrolopyrimidines as protein kinase inhibitors
AU2003254053A8 (en)	2004-02-09	Pyrazolopyrimidines as protein kinase inhibitors
IL141866A0 (en)	2002-03-10	Pyrrolopyrimidines as protein kinase inhibitors
IL161516A0 (en)	2004-09-27	Benzimidazoles useful as protein kinase inhibitors
AU2000240570A1 (en)	2001-10-08	Pyrrolopyrimidines as tyrosine kinase inhibitors
AU2002334355A1 (en)	2003-03-18	Protein tyrosine kinase inhibitors
IL208520A0 (en)	2010-12-30	Akt protein kinase inhibitors
EP1543009A4 (en)	2007-08-08	Pyrrolotriazine kinase inhibitors
PL369728A1 (en)	2005-05-02	Pyrrolopyrimidines as phosphodiesterase vii inhibitors
IL174948A0 (en)	2006-08-20	Imidazopyrazine tyrosine kinase inhibitors
AP2003002816A0 (en)	2003-06-30	Pyrazole compounds useful as protein kinase inhibitors
PL361676A1 (en)	2004-10-04	Pyrazole compounds useful as protein kinase inhibitors
AU2002357193A1 (en)	2003-07-09	Thienopyrimidine compounds as protein tyrosine kinase inhibitors
AU2003254051A8 (en)	2004-02-09	Pyrazolopyrimidines as kinase inhibitors
AU2002953255A0 (en)	2003-01-02	Protein kinase inhibitors
AU2001247882A1 (en)	2001-10-08	Tricyclic protein kinase inhibitors
AU2003261204A1 (en)	2004-02-09	Pyrazolopyrimidines as kinase inhibitors
IL144583A0 (en)	2002-05-23	Chimeric protein kinase inhibitors
AU2003260787A1 (en)	2004-03-29	Protein kinases
AUPS251502A0 (en)	2002-06-13	Protein kinase inhibitors
GB0101686D0 (en)	2001-03-07	Cyclin dependent kinase inhibitors
IL145329A0 (en)	2002-06-30	Protein tyrosine kinase inhibitors
AU2002355906A1 (en)	2003-03-03	Thiopyrane-4-ones as dna protein kinase inhibitors
AU2002953330A0 (en)	2003-01-09	Protein kinase inhibitors